Trials

HuMax-CD38 Safety Study in Multiple Myeloma - Open Label, First in humans, Dose-Escalation Followed by Open Label, Randomised, Parallel Group

Cancer type: Myeloma

Phase: I

Principal Investigator: Gimsing Peter

Country: DK

Keywords: Denmark, Rigshospitalet, anti-CD38, multiple myeloma

Status: Completed

Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT00574288?term=NCT00574288&rank=1